These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35839597)

  • 1. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
    Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
    Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations.
    Yan S; Zhao W; Dong Y; Wang H; Xu S; Yu T; Tao W
    World J Surg Oncol; 2024 Sep; 22(1):248. PubMed ID: 39267055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer.
    Zhao Y; Chen X; Wang Y; Zhang X; Ye Y; Xu S; Zhou L; Lin Y; Lu J; Yin W
    Ann Med; 2024 Dec; 56(1):2409343. PubMed ID: 39376056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
    Tarantino P; Niman SM; Erick TK; Priedigkeit N; Harrison BT; Giordano A; Nakhlis F; Bellon JR; Parker T; Strauss S; Jin Q; King TA; Overmoyer BA; Curigliano G; Regan MM; Tolaney SM; Lynce F
    Eur J Cancer; 2022 Oct; 174():277-286. PubMed ID: 36116830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
    Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
    Chen M; Chen W; Liu D; Chen W; Shen K; Wu J; Zhu L
    Breast Cancer; 2022 Sep; 29(5):844-853. PubMed ID: 35729304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
    Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
    Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of HER2-low expression in HER2-negative breast cancer under different hormone receptor status.
    Xu B; Shen J; Shen J; Wang L
    Int J Clin Oncol; 2023 Apr; 28(4):543-549. PubMed ID: 36723789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into HER2-low breast cancer brain metastasis: A retrospective analysis.
    Xu H; Wang Y; Li L; Han Y; Wu Y; Sa Q; Xu B; Wang J
    Breast; 2024 Feb; 73():103669. PubMed ID: 38176304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.
    Gaudio M; Jacobs F; Benvenuti C; Saltalamacchia G; Gerosa R; De Sanctis R; Santoro A; Zambelli A
    Breast Cancer Res Treat; 2024 Feb; 203(3):487-495. PubMed ID: 37923964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
    Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E
    ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.